Differential approach to primary open-angle glaucoma treatment

Abstract

PURPOSE: To evaluate Prolatan effectiveness in groups of patients with risk of glaucoma progression. METHODS: We used Moriscos-Green/Blank clinical and psychological tests-scales of compliance to assess 190 patients with primary open-angle glaucoma (POAG). We revealed 57 out of 190 POAG patients (30%) to be insufficiently committed to their treatment. Among them were 22 (38%) women and 35 (62%) men with mean age 64.4±2.5 years. 18 (32%) patients were diagnosed with glaucoma within the last month before admission, while 39 (68%) patients had progressive glaucoma. All patients underwent standard ophthalmic examination and additional Humphrey standard automated perimetry (threshold 30-2 strategy) at baseline and after 3 months. RESULTS: Statistically significant non-compliance factors were the following: age over 60, male gender, POAG duration from 3 to 10 years, comorbid pathology, regimens comprising a large number of drugs, mild glaucoma, cognitive impairment and financial difficulties, hindering the purchase of medicinal products. On the average, Prolatan decreased IOP level by 33%. By the end of the 3rd month our study revealed retinal light sensitivity increase in all sectors of the visual field from 0 to 30 degrees due to IOP stabilization. CONCLUSION: Prolatan increases adherence to treatment by the end of the 3rd month of follow-up, which is associated with a reduction in the number of instillations, no side effects after instillation, patients’ good health during the treatment course, reduction of treatment material costs.